The letter by Lieberman et al presents a new and interesting perspective on the studies of bromocriptine in the treatment of TD. Bromocriptine is believed to be a partial DA agonist. The main rationale for using low-dose bromocriptine in patients with TD has been a putative dopamine autoreceptor stimulation produced by the drug.1 Such an action would be expected to inhibit the synthesis and release of dopamine.2 Lieberman et al suggest that the relative inefficacy of bromocriptine in two reports1,3 may be attributable to the study design, while the beneficial effects of the drug in the third study4 might be explained on the basis of the attractive hypothesis of receptor sensitivity modification as postulated by Alpert and Friedhoff.5The explanation offered by Lieberman et al is quite plausible. It is likely that the doses of bromocriptine used in the earlier trials (10 mg or higher) were
Jeste DV, Wyatt RJ. Is Bromocriptine a Dopamine Antagonist Treatment?-Reply. Arch Gen Psychiatry. 1983;40(4):470. doi:10.1001/archpsyc.1983.01790040124024
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.